N H Hanna
Overview
Explore the profile of N H Hanna including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
366
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khanal N, Ahmed S, Kalra M, Miller T, Brames M, Stump T, et al.
Support Care Cancer
. 2019 Nov;
28(7):3165-3170.
PMID: 31707501
Background: It is important to assess the prevalence of hypogonadism and to identify the correlation between hypogonadism and cancer treatment with quality of life (QoL) in germ cell tumor (GCT)...
2.
Albany C, Adra N, Snavely A, Cary C, Masterson T, Foster R, et al.
Ann Oncol
. 2017 Nov;
29(2):341-346.
PMID: 29140422
Background: To report our experience utilizing a multidisciplinary clinic (MDC) at Indiana University (IU) since the publication of the International Germ Cell Cancer Collaborative Group (IGCCCG), and to compare our...
3.
Adra N, Einhorn L, Althouse S, Ammakkanavar N, Musapatika D, Albany C, et al.
Ann Oncol
. 2017 Oct;
29(1):209-214.
PMID: 29045540
Background: Despite remarkable results with salvage standard-dose or high-dose chemotherapy ∼15% of patients with relapsed germ-cell tumors (GCT) are incurable. Immune checkpoint inhibitors have produced significant remission in multiple tumor...
4.
Lesaffre E, Edelman M, Hanna N, Park K, Thatcher N, Willemsen S, et al.
Ann Oncol
. 2017 Feb;
28(7):1419-1426.
PMID: 28184431
Background: Pre-planned futility analyses are commonly used in oncology studies. The LUME-Lung 2 study (NCT00806819; 1199.14) was stopped early based on a pre-planned, non-binding futility analysis of investigator-assessed progression-free survival...
5.
Adra N, Althouse S, Liu H, Brames M, Hanna N, Einhorn L, et al.
Ann Oncol
. 2016 Feb;
27(5):875-9.
PMID: 26861605
Background: Based on the risk stratification from the International Germ Cell Cancer Collaborative Group (IGCCCG), only 14% of patients with metastatic germ-cell tumors (GCT) had poor-risk disease with a 5-year...
6.
Blumenschein Jr G, Smit E, Planchard D, Kim D, Cadranel J, De Pas T, et al.
Ann Oncol
. 2015 Feb;
26(5):894-901.
PMID: 25722381
Background: KRAS mutations are detected in 25% of non-small-cell lung cancer (NSCLC) and no targeted therapies are approved for this subset population. Trametinib, a selective allosteric inhibitor of MEK1/MEK2, demonstrated...
7.
Moore A, Einhorn L, Estes D, Govindan R, Axelson J, Vinson J, et al.
Lung Cancer
. 2006 Feb;
52(1):93-7.
PMID: 16488055
Background: Gefitinib has demonstrated activity in patients with non-small cell lung cancer (NSCLC). Clinical trials have not demonstrated a relationship between response to gefitinib and over-expression of the epidermal growth...
8.
Hanna N, Sandier A, Loehrer Sr P, Ansari R, Jung S, Lane K, et al.
Ann Oncol
. 2002 Feb;
13(1):95-102.
PMID: 11863118
Background: We performed this phase III study to determine whether the addition of 3 months of oral etoposide in non-progressing patients with extensive small-cell lung cancer (SCLC) treated with four...
9.
Hanna N
C R Acad Hebd Seances Acad Sci D
. 1975 Oct;
281(14):1003-5.
PMID: 813864
Laying and nesting start in winter. The society is strictly polygynous. All the fertilized females participate in the laying. After the nuptial flight, the founders cohabit and together form a...